San Diego-based mostly Viking Therapeutics marked alone as a serious competitor while in the weight loss drug current market in February just after revealing promising knowledge from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection and in March t